Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002
Nucleic Acid Ther. 2024 Jul 3. doi: 10.1089/nat.2024.0005. Online ahead of print. ABSTRACT Although MYCN has been considered an undruggable target, MYCN alterations confer poor …